Quoin Pharmaceuticals, Ltd. Logo

Quoin Pharmaceuticals, Ltd.

Clinical-stage pharma developing therapies for rare and orphan diseases like Netherton Syndrome.

QNRX | US

Overview

Corporate Details

ISIN(s):
US74907L1026 (+1 more)
LEI:
Country:
United States of America
Address:
23 HATA'AS STREET, 44425 KFAR SABA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Quoin Pharmaceuticals, Ltd. is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of therapeutic products for rare and orphan diseases. The company is advancing its lead product candidate, QRX003, through pivotal clinical studies for the treatment of Netherton Syndrome. Quoin Pharmaceuticals employs a patient-centric business strategy, aiming to ensure global access to its therapies. This is supported by exclusive international marketing and distribution partnerships covering approximately 60 countries, which augment its planned commercial infrastructure for the United States, Europe, and Japan.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Quoin Pharmaceuticals, Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Quoin Pharmaceuticals, Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Quoin Pharmaceuticals, Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Medigene AG Logo
Clinical-stage immuno-oncology firm developing TCR-engineered T cell therapies for solid tumors.
Germany
MDG1
MedinCell S.A. Logo
Develops long-acting injectable therapies using proprietary technology to impact global health.
France
MEDCL
A CDMO for cell therapy and regenerative medicine development & manufacturing.
Japan
2370
Medios AG Logo
Compounding patient-specific therapies and supplying specialty pharma for complex conditions.
Germany
ILM1
Develops cord blood stem cell therapies for osteoarthritis & infant lung disease, plus banking.
South Korea
078160
MediWound Ltd. Logo
Develops enzymatic therapies for non-surgical tissue repair in burns and chronic wounds.
United States of America
MDWD
Medizen Humancare Inc Co., Ltd Logo
Offers DTC genetic testing and genomic analysis for personalized disease risk prediction.
South Korea
236340
Medy-Tox Inc. Logo
Develops and markets botulinum toxins and dermal fillers for global aesthetic & therapeutic use.
South Korea
086900
MeiraGTx Holdings plc Logo
Develops genetic medicines for eye, salivary gland, and CNS disorders using gene regulation tech.
United States of America
MGTX
Meito  Sangyo  Co., Ltd. Logo
Produces food products and specialty chemicals for industrial and pharmaceutical applications.
Japan
2207

Talk to a Data Expert

Have a question? We'll get back to you promptly.